Eric Bell Email & Phone Number

Cambridge, Ma, Us

• Developed the tactical and operational plan for in vivo pharmacology and translational efforts of Rectify's hepatobiliary programs• Generated and characterized two mouse models of hepatobiliary disease and used them to deliver in vivo PoC for first-in-class ABCB11/B4 dual PFM • Developed translational plans for core pipeline programs and programs that are external opportunities • Identified and facilitated outreach to KOLs for scientific feedback and HCP perspective for hepatobiliary diseases, ectopic calcification disorders, rare ophthalmology diseases, and rare CNS/PNS diseases.• Collaborated with colleagues to develop the ABC transporter knowledgebase culminating in a Trends in Molecular Medicine publication

Cambridge, Ma, Us

Watertown, Massachusetts, Us

• Responsible for translational science efforts in rare benign hematology • Leading translational science for etavopivat clinical development team and contributing to the scientific strategy for life cycle management• Developed in vivo pharmacology and translational strategy for rare benign hematology discovery programs• Delivered data package for a no-go decision on a discovery program saving multi-million-dollar investment on an IDD contract • Influenced scientific objectives of clinical exploratory endpoints through development and execution of an advisory board meeting

• Drove the execution of research strategy developed as a consultant utilizing one internal direct report and external resources to reach a GO decision in polycystic kidney disease• Identified in vivo PKD models, initiated a breeding program for a genetic model at a CRO, and nominated small molecules based on in vitro activity, ADME, safety, and PK properties for in vivo evaluation• Developed integrated timelines for in vitro and in vivo activities with overall company timelines and corporate goals, presented work to upper management and involved in presenting to investors• Demonstrated translatability from in vitro to in vivo models of target engagement markers/biomarkers

• Identified and developed a research strategy in peripheral indications to evaluate and validate a novel protein chaperone target • Established and executed in vitro strategy to identify target engagement markers and suitable biomarkers for pre-clinical translational work

HotSpot Therapeutics: Advise on CRO selection and oversee work, review data and experimental designMitobridge: Preparation and writing of biomarker IND report Modulus: Due diligence and competitive intelligence of oncology target, with an emphasis on pharmacology, differentiation from related targets, and enabling assaysBantam Pharmaceutical: Interrogated MoA of small molecule oncology program

• Program Co-Lead responsible for concept, target validation, assay development and in vivo proof of concept studies of a small molecule program targeting Bach1 in sickle cell disease • Completed several key pharmacology studies and IND reports (cellular pharmacology, in vivo pharmacology, and biomarker) for PPARδ program (MA-0211 for Duchenne Muscular Dystrophy and Mitochondrial Myopathy)• Engaged and recruited key opinion leaders in sickle cell disease, mitochondrial myopathy, and fatty acid oxidation for advisory board and preclinical strategy• Managed assay development, pharmacodynamic experiments, PK/PD correlation, and in vivo proof of concept experiments at CROs and with academic collaborators• Lead the design and execution of GO/NO GO study implicating mitochondrial function in Chronic Fatigue Syndrome• Identified an indication expansion opportunity for a lead compound by implicating mitochondria modulation from metabolomics data set on patient plasma samples• Supervised a small multidisciplinary team and was promoted 3 times• This work resulted so far in two peer-reviewed publications and two patent applications

Cambridge, Ma, Us

Research Scientist (8/2013-8/2014)Postdoctoral Fellow (8/2007-7/2013)Investigated the molecular genetics of aging and diseases of aging, with a focus on Sirtuins. Utilized both tissue culture systems and genetically engineered mouse models. Gained significant experience in metabolism and proteomics.• Work resulted in fourteen peer-reviewed publications and one patent• Discovered SirT3 is a viable therapeutic strategy in cancer and diseases driven by hypoxia-inducible factor, and developed a mouse model to show feasibility.• Major collaboration resulted in the discovery of reductive glutamine metabolism and its therapeutic potential in oncology• Identified a major role for SirT1 in male germ cell differentiation, and as a therapeutic target for male contraception• Supervised, trained and mentored four students and a visiting professor• Managed animal protocols and served as lab representative for MIT Committee on Animal Care

Investigated cellular oxygen sensing and biological outcomes to hypoxia.• Acquired 2 fellowships and 1 travel award, published 11 manuscripts in peer-reviewed journals.• Successfully Identified mitochondria as the cellular oxygen sensor.• Identified that HIF is necessary for the hypoxic extension of replicative lifespan and sufficient for normoxic extension of replicative lifespan.

Responsible for basic lab management.• Published 2 manuscripts.• Investigated the resident proteins of cardiac caveolae.

Us

Validated and performed metabolite extraction from biological samples.Prepared standards and extracted metabolites for LC-MS/MS.

Doctor Of Philosophy (Phd), Cell And Molecular Biology, Cancer Biology

Bachelor Of Science (B.S.), Biology, Biotechnology